Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors

Advanced Drug Delivery Reviews

Volumn 65, Issue 9, 2013, Pages 1204-1214

  Arima, Hidetoshi ^a   Motoyama, Keiichi ^a   Higashi, Taishi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cyclodextrin; DNA; Gene delivery; Glucronylglucosyl cyclodextrin; Polyamidoamine dendrimer; Polypseudorotaxane

Indexed keywords

CYCLODEXTRINS; DNA; GENE TRANSFER; GENES;

AVERAGE DEGREE; BETA-CYCLODEXTRIN; GENE DELIVERY; GENE TRANSFER ACTIVITY; NONVIRAL VECTORS; POLYAMIDOAMINE DENDRIMERS; POLYPSEUDOROTAXANES; RESISTANT GENES;

DENDRIMERS;

ALANINE AMINOTRANSFERASE; ASIALOGLYCOPROTEIN RECEPTOR; ASPARTATE AMINOTRANSFERASE; CONCANAVALIN A; CYCLODEXTRIN; DENDRIMER; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE BINDING PROTEIN; FOLATE RECEPTOR; FOLIC ACID; FUCOSE RECEPTOR; HERMES ANTIGEN; LACTATE DEHYDROGENASE; LECTIN; LIPOSOME; MANNOSE; MANNOSE RECEPTOR; N ACETYLGALACTOSAMINE; NANOPARTICLE; PACLITAXEL; PLASMID DNA; POLYAMIDOAMINE; RECEPTOR; SHORT HAIRPIN RNA; SINGLE STRANDED DNA; SMALL INTERFERING RNA; SUGAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG MECHANISM; DRUG TRANSPORT; ENZYMATIC DEGRADATION; ENZYME STABILITY; GENE EXPRESSION; LIVER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RNA INTERFERENCE;

AMYLOIDOGENIC TRANSTHYRETIN; ASGPR; ASIALOGLYCOPROTEIN RECEPTOR; ATTR; BOVINE SERUM ALBUMIN; BSA; CDP; CYCLODEXTRIN; CYCLODEXTRINS; CYDS; DENDRIMER CONJUGATES WITH Α-CYD; DNA; FOLATE RECEPTOR; FR; FUC-R; FUCOSE RECEPTOR; GAL-Α-CDE; GALACTOSE-APPENDED Α-CDE; GALNAC; GENE DELIVERY; GLCNAC; GLUCRONYLGLUCOSYL-Β-CYCLODEXTRIN; LIPOPOLYSACCHARIDE; LPS; MANNOSE RECEPTOR; MR; N-ACETYL-D-GLUCOSAMINE; N-ACETYLGALACTOSAMINE; PAMAM; PDNA; PEI; PLASMID PDNA; PLL; POLY-L-LYSINE; POLYAMIDOAMINE; POLYAMIDOAMINE DENDRIMER; POLYETHYLENEIMINE; POLYPSEUDOROTAXANE; TRANSTHYRETIN; TTR; Α-CDES; Α-CYCLODEXTRIN; Α-CYD; Β-CYCLODEXTRIN; Β-CYD; Β-CYD-CONTAINING POLYCATIONS;

ANIMALS; ANTIGEN-PRESENTING CELLS; CARBOHYDRATES; CYCLODEXTRINS; DENDRIMERS; DNA; GENE TRANSFER TECHNIQUES; HEPATOCYTES; HUMANS;

EID: 84884288092     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.04.001     Document Type: Review

References (108)

1. Pfeifer C., Hasenpusch G., Uezguen S., Aneja M.K., Reinhardt D., Kirch J., Schneider M., Claus S., Friess W., Rudolph C. Dry powder aerosols of polyethylenimine (PEI)-based gene vectors mediate efficient gene delivery to the lung. J. Control. Release 2011, 154:69-76.
2. van Gaal E.V., Oosting R.S., van Eijk R., Bakowska M., Feyen D., Kok R.J., Hennink W.E., Crommelin D.J., Mastrobattista E. DNA nuclear targeting sequences for non-viral gene delivery. Pharm. Res. 2011, 28:1707-1722.
3. Van Tendeloo V.F., Van Broeckhoven C., Berneman Z.N. Gene therapy: principles and applications to hematopoietic cells. Leukemia 2001, 15:523-544.
4. Tiera M.J., Shi Q., Winnik F.M., Fernandes J.C. Polycation-based gene therapy: current knowledge and new perspectives. Curr. Gene Ther. 2011, 11:288-306.
5. Xu Q., Wang C.H., Pack D.W. Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. Curr. Pharm. Des. 2010, 16:2350-2368.
6. Tomalia D., Baker H., Dewald J., Hall M., Kallos G., Martin S., Roek J., Ryder J., Smith P. A new class of polymers: starburt-dendritic macromolecules. Polym. J. 1985, 17:117-132.
7. Mintzer M.A., Grinstaff M.W. Biomedical applications of dendrimers: a tutorial. Chem. Soc. Rev. 2011, 40:173-190.
8. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R., Tomalia D.A., Baker J.R. Efficient transfer of genetic material into mammalian cells using starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:4897-4902.
9. Haensler J., Szoka F.C. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem. 1993, 4:372-379.
10. Wang P., Zhao X.H., Wang Z.Y., Meng M., Li X., Ning Q. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment. Cancer Lett. 2010, 298:34-49.
11. Shcharbin D., Pedziwiatr E., Blasiak J., Bryszewska M. How to study dendriplexes II: transfection and cytotoxicity. J. Control. Release 2010, 141:110-127.
12. Jones C.F., Campbell R.A., Franks Z., Gibson C.C., Thiagarajan G., Vieira-de-Abreu A., Sukavaneshvar S., Mohammad S.F., Li D.Y., Ghandehari H., Weyrich A.S., Brooks B.D., Grainger D.W. Cationic PAMAM dendrimers disrupt key platelet functions. Mol. Pharm. 2012, 9:1599-1611.
13. Chauhan A.S., Diwan P.V., Jain N.K., Tomalia D.A. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules 2009, 10:1195-1202.
14. Saenger W. Stereochemistry of circularly closed oligosaccharides: cyclodextrin structure and function. Biochem. Soc. Trans. 1983, 11(Pt. 2):136-139.
15. Szejtli J. Medicinal applications of cyclodextrins. Med. Res. Rev. 1994, 14:353-386.
16. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998, 98:2045-2076.
17. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86:147-162.
18. Irie T., Uekama K. Cyclodextrins in peptide and protein delivery. Adv. Drug Deliv. Rev. 1999, 36:101-123.
19. Marttin E., Verhoef J.C., Merkus F.W. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 1998, 6:17-36.
20. Ilangumaran S., Hoessli D.C. Effects of cholesterol depletion by cyclodextrin on the sphingolipid microdomains of the plasma membrane. Biochem. J. 1998, 335(Pt. 2):433-440.
21. Rodal S.K., Skretting G., Garred O., Vilhardt F., van Deurs B., Sandvig K. Extraction of cholesterol with methyl-β-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell 1999, 10:961-974.
22. Camargo F., Erickson R.P., Garver W.S., Hossain G.S., Carbone P.N., Heidenreich R.A., Blanchard J. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci. 2001, 70:131-142.
23. Vance J.E., Peake K.B. Function of the Niemann-Pick type C proteins and their bypass by cyclodextrin. Curr. Opin. Lipidol. 2011, 22:204-209.
24. Yang C., Wang X., Li H., Goh S.H., Li J. Synthesis and characterization of polyrotaxanes consisting of cationic α-cyclodextrins threaded on poly[(ethylene oxide)-ran-(propylene oxide)] as gene carriers. Biomacromolecules 2007, 8:3365-3374.
25. Zhang W., Chen Z., Song X., Si J., Tang G. Low generation polypropylenimine dendrimer graft β-cyclodextrin: an efficient vector for gene delivery system. Technol. Cancer Res. Treat. 2008, 7:103-108.
26. Huang H., Tang G., Wang Q., Li D., Shen F., Zhou J., Yu H. Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-β-cyclodextrin or (2-hydroxypropyl)-γ-cyclodextrin. Chem. Commun. (Camb.) 2006, 2382-2384.
27. Tang G.P., Guo H.Y., Alexis F., Wang X., Zeng S., Lim T.M., Ding J., Yang Y.Y., Wang S. Low molecular weight polyethylenimines linked by β-cyclodextrin for gene transfer into the nervous system. J. Gene Med. 2006, 8:736-744.
28. Ooya T., Choi H.S., Yamashita A., Yui N., Sugaya Y., Kano A., Maruyama A., Akita H., Ito R., Kogure K., Harashima H. Biocleavable polyrotaxane-plasmid DNA polyplex for enhanced gene delivery. J. Am. Chem. Soc. 2006, 128:3852-3853.
29. Yang C., Li H., Wang X., Li J. Cationic supramolecules consisting of oligoethylenimine-grafted α-cyclodextrins threaded on poly(ethylene oxide) for gene delivery. J. Biomed. Mater. Res. A 2009, 89:13-23.
30. Teijeiro-Osorio D., Remunan-Lopez C., Alonso M.J. Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro. Eur. J. Pharm. Biopharm. 2009, 71:257-263.
31. Zhou Y., Wang H., Wang C., Li Y., Lu W., Chen S., Luo J., Jiang Y., Chen J. Receptor-mediated, tumor-targeted gene delivery using folate-terminated polyrotaxanes. Mol. Pharm. 2012, 9:1067-1076.
32. Hu Y., Tang G., Liu J., Cheng W., Yue Y., Li J., Zhang P. FGF receptor-mediated gene delivery using ligands coupled to PEI-β-CyD. J. Biomed. Biotechnol. 2012, 2012:989235.
33. Ping Y., Liu C., Zhang Z., Liu K.L., Chen J., Li J. Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials 2011, 32:8328-8341.
34. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem. 2003, 14:1122-1132.
35. Gonzalez H., Hwang S.J., Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjug. Chem. 1999, 10:1068-1074.
36. Pun S.H., Davis M.E. Development of a nonviral gene delivery vehicle for systemic application. Bioconjug. Chem. 2002, 13:630-639.
37. Hwang S.J., Bellocq N.C., Davis M.E. Effects of structure of β-cyclodextrin-containing polymers on gene delivery. Bioconjug. Chem. 2001, 12:280-290.
38. Reineke T.M., Davis M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 2. Charge center type. Bioconjug. Chem. 2003, 14:255-261.
39. Reineke T.M., Davis M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconjug. Chem. 2003, 14:247-254.
40. Popielarski S.R., Mishra S., Davis M.E. Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization. Bioconjug. Chem. 2003, 14:672-678.
41. Mishra S., Heidel J.D., Webster P., Davis M.E. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. J. Control. Release 2006, 116:179-191.
42. Pun S.H., Tack F., Bellocq N.C., Cheng J., Grubbs B.H., Jensen G.S., Davis M.E., Brewster M., Janicot M., Janssens B., Floren W., Bakker A. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 2004, 3:641-650.
43. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
44. Bartlett D.W., Davis M.E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 2008, 99:975-985.
45. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., Kornbrust D.J., Davis M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5715-5721.
46. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15549-15554.
47. Bartlett D.W., Davis M.E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 2007, 18:456-468.
48. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
49. Ortiz Mellet C., Garcia Fernandez J.M., Benito J.M. Cyclodextrin-based gene delivery systems. Chem. Soc. Rev. 2011, 40:1586-1608.
50. Arima H., Motoyama K., Higashi T. Polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for DNA, shRNA and siRNA. Pharmaceutics 2012, 4:130-148.
51. Niederhafner P., Reinis M., Sebestik J., Jezek J. Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J. Pept. Sci. 2008, 14:556-587.
52. Niederhafner P., Sebestik J., Jezek J. Peptide dendrimers. J. Pept. Sci. 2005, 11:757-788.
53. Niederhafner P., Sebestik J., Jezek J. Glycopeptide dendrimers. Part II. J. Pept. Sci. 2008, 14:44-65.
54. Arima H., Motoyama K., Higashi T. Potential use of polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for siRNA. Pharmaceuticals 2012, 5:61-78.
55. Pack D.W., Hoffman A.S., Pun S., Stayton P.S. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 2005, 4:581-593.
56. Tros de Ilarduya C., Sun Y., Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur. J. Pharm. Sci. 2010, 40:159-170.
57. Arima H., Kihara F., Hirayama F., Uekama K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with α-, β-, and γ-cyclodextrins. Bioconjug. Chem. 2001, 12:476-484.
58. Ohtani Y., Irie T., Uekama K., Fukunaga K., Pitha J. Differential effects of α-, β-, 18 and γ-cyclodextrins on human erythrocytes. Eur. J. Biochem. 1989, 186:17-22.
59. Kihara F., Arima H., Tsutsumi T., Hirayama F., Uekama K. In vitro and in vivo gene transfer by an optimized α-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug. Chem. 2003, 14:342-350.
60. Kihara F., Arima H., Tsutsumi T., Hirayama F., Uekama K. Effects of structure of polyamidoamine dendrimer on gene transfer efficiency of the dendrimer conjugate with α-cyclodextrin. Bioconjug. Chem. 2002, 13:1211-1219.
61. Tsutsumi T., Hirayama F., Uekama K., Arima H. Potential use of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA. J. Pharm. Sci. 2008, 97:3022-3034.
62. Arima H., Tsutsumi T., Yoshimatsu A., Ikeda H., Motoyama K., Higashi T., Hirayama F., Uekama K. Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) on endogenous gene expression. Eur. J. Pharm. Sci. 2011, 44:375-384.
63. Tsutsumi T., Hirayama F., Uekama K., Arima H. Evaluation of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J. Control. Release 2007, 119:349-359.
64. Roessler B.J., Bielinska A.U., Janczak K., Lee I., Baker J.R. Substituted β-cyclodextrins interact with PAMAM dendrimer-DNA complexes and modify transfection efficiency. Biochem. Biophys. Res. Commun. 2001, 283:124-129.
65. Menuel S., Fontanay S., Clarot I., Duval R.E., Diez L., Marsura A. Synthesis and complexation ability of a novel bis-(guanidinium)-tetrakis-(β-cyclodextrin) dendrimeric tetrapod as a potential gene delivery (DNA and siRNA) system. Study of cellular siRNA transfection. Bioconjug. Chem. 2008, 19:2357-2362.
66. Xu X., Zhang Y., Wang X., Guo X., Zhang X., Qi Y., Shen Y.M. Radiosynthesis, biodistribution and micro-SPECT imaging study of dendrimer-avidin conjugate. Bioorg. Med. Chem. 2011, 19:1643-1648.
67. Gazi U., Martinez-Pomares L. Influence of the mannose receptor in host immune responses. Immunobiology 2009, 214:554-561.
68. Woller E.K., Cloninger M.J. The lectin-binding properties of six generations of mannose-functionalized dendrimers. Org. Lett. 2002, 4:7-10.
69. Schlick K.H., Udelhoven R.A., Strohmeyer G.C., Cloninger M.J. Binding of mannose-functionalized dendrimers with pea (Pisum sativum) lectin. Mol. Pharm. 2005, 2:295-301.
70. Schlick K.H., Morgan J.R., Weiel J.J., Kelsey M.S., Cloninger M.J. Clusters of ligands on dendrimer surfaces. Bioorg. Med. Chem. Lett. 2011, 21:5078-5083.
71. Sheng K.C., Kalkanidis M., Pouniotis D.S., Esparon S., Tang C.K., Apostolopoulos V., Pietersz G.A. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol. 2008, 38:424-436.
72. Dutta T., Agashe H.B., Garg M., Balakrishnan P., Kabra M., Jain N.K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 2007, 15:89-98.
73. Wada K., Arima H., Tsutsumi T., Chihara Y., Hattori K., Hirayama F., Uekama K. Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates. J. Control. Release 2005, 104:397-413.
74. Arima H., Chihara Y., Arizono M., Yamashita S., Wada K., Hirayama F., Uekama K. Enhancement of gene transfer activity mediated by mannosylated dendrimer/α-cyclodextrin conjugate (generation 3, G3). J. Control. Release 2006, 116:64-74.
75. Capecchi M.R. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980, 22:479-488.
76. Nguyen T.H., Ferry N. Liver gene therapy: advances and hurdles. Gene Ther. 2004, 11(Suppl. 1):S76-S84.
77. Kaneda Y., Iwai K., Uchida T. Introduction and expression of the human insulin gene in adult rat liver. J. Biol. Chem. 1989, 264:12126-12129.
78. Wu G.Y., Wu C.H. Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 1988, 263:14621-14624.
79. Nakatani T., Kuriyama S., Tominaga K., Tsujimoto T., Mitoro A., Yamazaki M., Tsujinoue H., Yoshiji H., Nagao S., Fukui H. Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers. Gut 2000, 47:563-570.
80. Cheng L., Ziegelhoffer P.R., Yang N.S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:4455-4459.
81. Rettinger S.D., Kennedy S.C., Wu X., Saylors R.L., Hafenrichter D.G., Flye M.W., Ponder K.P. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1460-1464.
82. Wu G.Y., Wu C.H. Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochemistry 1988, 27:887-892.
83. Westerlind U., Westman J., Tornquist E., Smith C.I., Oscarson S., Lahmann M., Norberg T. Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine. Glycoconj. J. 2004, 21:227-241.
84. Hu H.M., Zhang X., Zhong N.Q., Pan S.R. Study on galactose-poly(ethylene glycol)-poly(l-lysine) as novel gene vector for targeting hepatocytes in vitro. J. Biomater. Sci. Polym. Ed. 2012, 23:677-695.
85. Qin Z., Liu W., Li L., Guo L., Yao C., Li X. Galactosylated N-2-hydroxypropyl methacrylamide-b-N-3-guanidinopropyl methacrylamide block copolymers as hepatocyte-targeting gene carriers. Bioconjug. Chem. 2011, 22:1503-1512.
86. Nie C., Liu C., Chen G., Dai J., Li H., Shuai X. Hepatocyte-targeted psiRNA delivery mediated by galactosylated poly(ethylene glycol)-graft-polyethylenimine in vitro. J. Biomater. Appl. 2011, 26:255-275.
87. Vargas-Berenguel A., Ortega-Caballero F., Santoyo-Gonzalez F., Garcia-Lopez J.J., Gimenez-Martinez J.J., Garcia-Fuentes L., Ortiz-Salmeron E. Dendritic galactosides based on a β-cyclodextrin core for the construction of site-specific molecular delivery systems: synthesis and molecular recognition studies. Chemistry 2002, 8:812-827.
88. McMahon A., O'Neill M.J., Gomez E., Donohue R., Forde D., Darcy R., O'Driscoll C.M. Targeted gene delivery to hepatocytes with galactosylated amphiphilic cyclodextrins. J. Pharm. Pharmacol. 2012, 64:1063-1073.
89. Wada K., Arima H., Tsutsumi T., Hirayama F., Uekama K. Enhancing effects of galactosylated dendrimer/α-cyclodextrin conjugates on gene transfer efficiency. Biol. Pharm. Bull. 2005, 28:500-505.
90. Vrasidas I. Synthesis of lactose dendrimers and multivalency effects in binding to the cholera toxin B subunit. Eur. J. Org. Chem. 2001, 2001:4685-4692.
91. Agashe H.B., Babbar A.K., Jain S., Sharma R.K., Mishra A.K., Asthana A., Garg M., Dutta T., Jain N.K. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers. Nanomedicine 2007, 3:120-127.
92. Arima H., Yamashita S., Mori Y., Hayashi Y., Motoyama K., Hattori K., Takeuchi T., Jono H., Ando Y., Hirayama F., Uekama K. In vitro and in vivo gene delivery mediated by lactosylated dendrimer/α-cyclodextrin conjugates (G2) into hepatocytes. J. Control. Release 2010, 146:106-117.
93. Motoyama K., Mori Y., Yamashita S., Hayashi Y., Jono H., Ando Y., Hirayama F., Uekama K., Arima H. In vitro gene delivery mediated by lactosylated dendrimer (generation 3, G3)/α-cyclodextrin conjugates into hepatocytes. J. Incl. Phenom. Macrocycl. Chem. 2011, 70:333-338.
94. Ishihara H., Hayashi Y., Hara T., Aramaki Y., Tsuchiya S., Koike K. Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-γ by human hepatoma cells and its inhibitory effect on hepatitis B virus replication. Biochem. Biophys. Res. Commun. 1991, 174:839-845.
95. Hayashi Y., Mori Y., Yamashita S., Motoyama K., Higashi T., Jono H., Ando Y., Arima H. Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. Mol. Pharm. 2012, 9:1645-1653.
96. Hayashi Y., Higashi T., Motoyama K., Mori Y., Jono H., Ando Y., Arima H. Design and evaluation of polyamidoamine dendrimer conjugate with PEG, α-cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo. J Drug Target 2013, (in press).
97. Higuchi Y., Kawakami S., Yamashita F., Hashida M. The potential role of fucosylated cationic liposome/NFκB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials 2007, 28:532-539.
98. Majoros I.J., Myc A., Thomas T., Mehta C.B., Baker J.R. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7:572-579.
99. Bezouska K., Kren V., Kieburg C., Lindhorst T.K. GlcNAc-terminated glycodendrimers form defined precipitates with the soluble dimeric receptor of rat natural killer cells, sNKR-P1A. FEBS Lett. 1998, 426:243-247.
100. Vannucci L., Fiserova A., Sadalapure K., Lindhorst T.K., Kuldova M., Rossmann P., Horvath O., Kren V., Krist P., Bezouska K., Luptovcova M., Mosca F., Pospisil M. Effects of N-acetyl-glucosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo. Int. J. Oncol. 2003, 23:285-296.
101. Medina S.H., Tekumalla V., Chevliakov M.V., Shewach D.S., Ensminger W.D., El-Sayed M.E. N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials 2011, 32:4118-4129.
102. Arima H., Arizono M., Higashi T., Yoshimatsu A., Ikeda H., Motoyama K., Hattori K., Takeuchi T., Hirayama F., Uekama K. Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with α-cyclodextrin as DNA carriers to tumor cells. Cancer Gene Ther. 2012, 19:358-366.
103. Ooya T., Ito A., Yui N. Preparation of α-cyclodextrin-terminated polyrotaxane consisting of β-cyclodextrins and pluronic as a building block of a biodegradable network. Macromol. Biosci. 2005, 5:379-383.
104. Higashi T., Hirayama F., Misumi S., Arima H., Uekama K. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system. Biomaterials 2008, 29:3866-3871.
105. Motoyama K., Hayashida K., Arima H. Potential use of polypseudorotaxanes of pegylated polyamidoamine dendrimer with cyclodextrins as novel sustained release systems for DNA. Chem. Pharm. Bull. 2011, 59:476-479.
106. Motoyama K., Hayashida K., Higashi T., Arima H. Polypseudorotaxanes of pegylated α-cyclodextrin/polyamidoamine dendrimer conjugate with cyclodextrins as a sustained release system for DNA. Bioorg. Med. Chem. 2012, 20:1425-1433.
107. Anno T., Higashi T., Motoyama K., Hirayama F., Uekama K., Arima H. Potential use of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo. J Drug Target 2012, 20:272-280.
108. Anno T., Higashi T., Motoyama K., Hirayama F., Uekama K., Arima H. Possible enhancing mechanisms for gene transfer activity of glucuronylglucosyl-β-cyclodextrin/dendrimer conjugate. Int. J. Pharm. 2012, 426:239-247.